Amended Current Report Filing (8-k/a)
August 03 2020 - 4:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 30, 2020
Royalty Pharma plc
(Exact Name of Registrant as Specified in
its Charter)
|
|
|
|
|
England and Wales
|
|
001-39329
|
|
Not Applicable
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
110 East 59th Street
New York, New York
|
|
|
|
10022
|
(Address of Principal Executive
Offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (212) 883-0200
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Securities
Exchange Act of 1934:
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which
registered
|
Class A Ordinary Shares, par
value $0.0001 per share
|
|
RPRX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported
on a Current Report on Form 8-K filed by Royalty Pharma plc (the “Company”) on June 16, 2020 (the “Form
8-K”), the Company’s Board of Directors (the “Board”) appointed Catherine Engelbert as a member of
the Board. At the time of her appointment, committee membership for Ms. Engelbert had not yet been determined. The Company hereby
amends Item 5.02 of the Form 8-K to report that on July 30, 2020, the Board, upon the recommendation of
the Company’s Nominating and Corporate Governance Committee, appointed Ms. Engelbert as a member of the Board’s Audit
Committee. No other changes have been made to the Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 3, 2020
ROYALTY PHARMA PLC
|
|
|
|
|
|
|
By:
|
|
/s/ Pablo Legorreta
|
|
|
|
Pablo Legorreta
|
|
|
|
Chief Executive Officer
|
|
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024